Combined treatment with anti-CTLA-4 antibody and tumor lysate-pulsed dendritic cells in mice with OS lead to decreased Tregs and increased CD8 T cells in metastatic tumor leading to decreased metastasis and increased EFS [33]. This evidence concerns the gene CD8A and metastatic neoplasm.